生物活性
Vatalanib是一种口服抗血管生成药物,可抑制血管内皮生长因子受体酪氨酸激酶,在患者中显示出代谢的自动诱导和药代动力学(PK)配置的变异。在较高浓度时,其他酪氨酸激酶也被抑制,包括PDGFR-β (IC50= 580 nM)、c-KIT (IC50= 730 nM)、FLT-4 (IC50= 660 nM)和c-FMS (IC5= 1.4μM)。另一方面,vatalanib对EGFR、c-SRC、v-ABL和蛋白激酶Cα (IC50> 10μM)没有活性。与历史对照组相比,Vatalanib作为二线治疗的耐受性良好,并导致转移性胰腺癌患者良好的6个月生存率。抑制剂Vatalanib可能是平滑肌肉瘤治疗的另一种选择。
化学数据
分子量 | 346.81 |
分子式 | C20H15ClN4 |
CAS号 | 212141-54-3 |
纯度 | >98% |
溶解性(25°C) | DMSO 25 mg/mL |
储存和运输条件 | 固体粉末: -20°C 冷藏长期储存 常温运输及临时存放 |
实验操作 来自于公开的文献,仅供相同实验参考(如实验材料、目的不同,请参考其他文献)
细胞实验 |
---|
细胞系 | HUVECs |
方法 | Endothelial Cell Proliferation Assays. As a test of the ability of PTK787/ZK 222584 to inhibit a functional response to VEGF, an endothelial cell proliferation assay, based on BrdUrd incorporation was used (Biotrak Cell Proliferation System V.2, Amersham, England). Subconfluent HUVECs were seeded at a density of 5 3 103 cells/well into 96-well plates coated with 1.5% gelatin and then incubated at 37°C and 5% CO2 in growth medium. After 24 h, growth medium was replaced by basal medium containing 1.5% FCS and a constant concentration of VEGF (50 ng/ml), bFGF (0.5 ng/ml), or FCS (5%), in the presence or absence of PTK787/ZK 222584. As a control, wells without growth factor were also included. After 24 h of incubation, BrdUrd labeling solution was added, and cells incubated an additional 24 h before fixation, blocking, and addition of peroxidase-labeled anti-BrdUrd antibody. Bound antibody was then detected using 3,395,59-tetramethylbenzidine substrate, which results in a colored reaction product that is quantified spectrophotometrically at 450 nm. |
浓度 | 0~1 μM |
处理时间 | 24 h |
动物实验 |
---|
动物模型 | Nude Mouse Human Tumor Xenograft Model |
配制 | distilled water |
剂量 | 25 to 100 mg/kg once or twice dail |
给药处理 | p.o. |
不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)
| 小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
储备液配制
以下数据基于产品分子量,对于特殊产品,请参照COA中的储备液配制条件和说明进行操作。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.8834 mL | 14.4171 mL | 28.8342 mL |
5 mM | 0.5767 mL | 2.8834 mL | 5.7668 mL |
10 mM | 0.2883 mL | 1.4417 mL | 2.8834 mL |